Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.49 |
| ▸ | NMBR | P28336 | 2/20 | 0.48 |
| ▸ | GRPR | P30550 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 1/20 | 0.47 |
| ▸ | SCTR | P47872 | 1/20 | 0.47 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30030378 | 0.96 | KISS1R (0.51) | OPRD1KISS1RNMBRGRPRGLP1R | |
| SCHEMBL30996216 | 0.96 | KISS1R (0.51) | OPRD1KISS1RNMBRGRPRGLP1R | |
| SCHEMBL31450045 | 0.96 | KISS1R (0.51) | OPRD1KISS1RNMBRGRPRGLP1R | |
| SCHEMBL30874972 | 0.95 | OPRD1 (0.53) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL30874946 | 0.92 | GLP1R (0.52) | OPRD1KISS1RGLP1R | |
| SCHEMBL30874967 | 0.92 | GLP1R (0.52) | OPRD1KISS1RGLP1R | |
| SCHEMBL29649710 | 0.91 | GLP1R (0.50) | OPRD1KISS1RNMBRGRPRGLP1R | |
| SCHEMBL31307293 | 0.87 | TFPI (0.56) | NMBRGRPRGLP1RSCTRTFPI | |
| SCHEMBL30974601 | 0.87 | TFPI (0.56) | NMBRGRPRGLP1RSCTRTFPI | |
| SCHEMBL30662034 | 0.87 | GLP1R (0.53) | OPRD1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099554-A1 | COMPOSITIONS AND METHODS OF FAS INHIBITION | ONL THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240156898-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4355349-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022266127-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156898-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | UACA, ASAH2, NFKBIA | OPRD1 4411/4885OPRM1 4732/4885OPRK1 3336/4885 |
| US-20250099554-A1 | COMPOSITIONS AND METHODS OF FAS INHIBITION | CFB, BAX, FASN | OPRD1 4243/4885OPRM1 4112/4885OPRK1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.